Table 2 Clinical characteristics, disease activity and treatment of RA patients
N | % | |
|---|---|---|
Gender | ||
Female | 147 | 78.61 |
Male | 40 | 21.39 |
Mean (SD) age (years) | 54.4 (10.8) | |
Mean (SD) time evolution (years) | 8.88 (7.32) | |
Early RA | 35 | 18.72 |
Established RA | 152 | 81.28 |
Rheumatoid factor | ||
Seropositive | 138 | 74.19 |
Rheumatoid factor concentration (IU/ml) | ||
Low (≤ 90) | 49 | 36.84 |
Moderate (91–300) | 56 | 42.11 |
High (> 300) | 28 | 21.05 |
Anti-CCP | ||
Positive | 114 | 67.86 |
Anti-CCP concentration (U/ml) | ||
Low (≤ 75) | 30 | 27.27 |
Moderate (76–300) | 43 | 39.09 |
High (> 300) | 37 | 33.64 |
Level of activity, mean (SD) | ||
DAS28 | 3.81(1.31) | |
DAS28-CRP | 3.18(1.18) | |
SDAI | 14.49(10.74) | |
CDAI | 12.68(10.19) | |
Disease activity (combined index) | ||
Remission | 38 | 20.32 |
Low | 39 | 20.90 |
Moderate | 85 | 45.45 |
High | 25 | 13.43 |
HAQ | 0.760 (0.62) | |
Glucocorticoid therapy | ||
No glucocorticoids | 99 | 52.94 |
Glucocorticoids | 88 | 47.06 |
Current dosage GC, mean (SD) (mg/day) | 2.85 (4.24) | |
Low < 7.5 | 65 | 73.86 |
Moderate 7.5–20 | 22 | 25 |
High > 20 | 1 | 1.14 |
Type of RA therapy | ||
No treatment | 10 | 5.35 |
sDMARDs | 99 | 52.94 |
≥ 2 sDMARDs | 22 | 11.76 |
bDMARDs | 56 | 29.95 |